NervGen Pharma Corp.

NervGen Pharma Corp. is a biotechnology company focused on discovering, developing, and commercializing pharmaceutical treatments to repair the nervous system following neurotrauma and neurologic disease. The company's primary product candidate is NVG-291, which is currently in a Phase 1b/2a clinical trial. This trial is evaluating NVG-291 for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease. Another product candidate, NVG-300, is in preclinical studies for ischemic stroke, amyotrophic lateral sclerosis, and a confirmatory SCI study. NervGen Pharma Corp. holds a licensing agreement with Case Western Reserve University, granting it rights to develop and commercialize a patented technology that shows therapeutic potential for spinal cord injury and other conditions involving nerve damage. The company was incorporated in 2017 and operates from its headquarters in Vancouver, Canada.